Lintuzumab
CAS No. : 166089-32-3
(Synonyms: SGN-33; HuM-195)
| Size | Price | Stock |
|---|---|---|
| 1mg | $200 | In-stock |
| 5mg | $560 | In-stock |
| 10mg | $815 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-P9983 |
| M.Wt: | 1000.00 |
| Formula: | N/A |
| Purity: | >98 % |
| Solubility: | H2O |
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice[1].
IC50 & Target:Siglec-3/CD33
In Vitro:Lintuzumab (5 μg/mL, 0.1-2 h) induces phosphorylation of CD33 and recruitment of Shp-1 phosphatase inHL60 cells[2].
Lintuzumab (2500 ng/mL) significantly decreases the production of tumorigenic growth factors including IL-8, MCP-1, IP-10 and RANTES in KG-1 cells[2].
Lintuzumab (0.1 ng/mL-10 μg/mL) exerts multiple effector functions including the ability to mediate ADCC and ADCP in AML cell lines[2].
In Vivo:Lintuzumab (3-30 mg/kg, i.v., 4 doses) significantly improves the survival of HL-60 xenograft mice compared to the control[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Lintuzumab
- Cat. No.:
- HY-P9983
- Quantity:
Your information is safe with us.